Sanofi and Regeneron announced they have "restructured" their US$2,17bn immunoncology collaboration. While the companies will continue co-marketing of the FDA approved (2018) PD1 blocker cemiplimab (REGN2810) as treatment for cutaneous squamous cell carcinoma, Sanofi will quit development of early stage antibody discovery programmes under the 2015 agreement.
Cells that line the blood vessels do not behave identically but instead exhibit varied responses to the same biochemical signals, British researchers report in Science.
Differences in microbiome composition can help to distinguish inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS), Dutch and US researchers report.
Cancer specialist Cellestia Biotech AG has secured CHF20m through a Series A financing led by FC Capital, and PPF / Sotio, and ETP Ventures, Boston & Beijing.
Staten Biotechnology has signed a dyslipidaemia licence option deal worth US$430m with Novo Nordisk.
Paris-based Kurma Partners announced the first closing of its Kurma Biofund III, a life science fund set to raise 150m.
The European Parliament has voted to add 36.5bn to the budget of Horizon Europe (94.1bn, in 2018 prices) proposed by the European Commission to foster research and innovation.
Cancer immunotherapies are often associated with severe cytokine release syndrome (CRS) that can be managed with IL-6R-blockers. US oncologists now report that an FDA-approved hypertension drug did the same job as Roche’s anti-IL-6R blocker tocolizumab.
Immuncheckpoint specialist Oxford BioTherapeutics has licenced the right to develop five bispecific antibodies for combination therapies using Wuxi Biologics WuXiBody platform.
An analysis of health records of the whole Scottish population aged ?30 years revealed that people with diabetes have an increased risk for heart failure.